Inflammatory bowel disease (IBD) is a chronic, inflammatory condition of the gastrointestinal tract. Patients with IBD present with debilitating symptoms that alter the quality of life and can develop into severe complications requiring surgery. Epidemiological evidence indicates Westernized societies have an elevated IBD burden when compared with Asian societies. Considering the stark contrast between the typical Western and Eastern dietary patterns, it is postulated that differences in food and lifestyle contribute to lower IBD incidence in Asian countries. Soybeans (Glycine max), which are consumed in high quantities and as various preparations in Eastern societies, contain a wealth of natural, biologically active compounds that include isoflavones, bioactive peptides, protease inhibitors, and phytosterols, among many others. These compounds have been shown to improve human health, and preclinical evidence suggests they have potential to improve the prognosis of IBD. This review summarizes the current state of evidence regarding the effects and the mechanisms of action of these soybean-derived bioactive compounds in experimental models of IBD.
INTRODUCTION
As the name suggests, inflammatory bowel disease (IBD) is an autoimmune disorder characterized by chronic inflammation of the gastrointestinal (GI) tract. Inflammatory bowel disease is traditionally diagnosed as 1 of 2 chronic diseases: Crohn disease or ulcerative colitis. Patients with ulcerative colitis present with a continuous segment of inflamed tissue, specifically in the colon and, more frequently, in the distal colon or rectum. Crohn disease, however, may present with inflammation in any segment of the GI tract, including the mouth and esophagus, though it is most commonly limited to the ileocolic region. Although the causative factors of IBD evade investigators, the pathophysiology is generally understood (Figure 1 ). In short, chronic mucosal inflammation, mediated by a dysregulated type 1 T-helper cell (Th1; Crohn disease) or type 2 T-helper cell (Th2; ulcerative colitis) immune response, causes loss of large and/or small bowel integrity and prevents regeneration of the epithelial barrier. As a result, luminal contents, including microbes and dietary antigens, easily permeate the intestine to activate mucosal immunity in the lamina propria. Even host bacteria, which are responsible for the maintenance of the intestinal barrier and protection from more harmful pathogenic microbes under homeostatic conditions, may translocate across the luminal barrier to propagate inflammation in the lamina propria.
The burden of IBD varies dramatically between regions of the world. In the United States, 1 survey estimates that 3.1 million adults, or approximately 1.3% of the adult population, have been diagnosed with IBD, 1 and a recent study concluded an additional 90 000 new cases are diagnosed each year. 2 Ulcerative colitis alone incurs $14.9 billion in costs on the US economy. 3 In contrast, Eastern countries are less burdened by IBD. In Japan, for instance, IBD is observed in only approximately 0.08% of the population. 4 Among the reported causes of IBD and factors of disease severity are the individual and combined effects of genetics, environmental factors, and lifestyle choices. Environmental factors, particularly diet, are thus central to the apparent EastWest dichotomy in IBD prevalence. 5 The Western dietary pattern, which is high in fat, refined grains, and red meat, is reported to exacerbate and possibly initiate IBD in vivo 6, 7 and correlates with a risk of developing IBD in humans. 8 Traditional pharmaceutical approaches to IBD, such as corticosteroids and immunosuppressant drugs, while effective at inducing and maintaining remission, are not without serious adverse effects (ie, opportunistic infections, gastrointestinal distress and bleeding, Cushing syndrome). 9 Dietary management of IBD represents a therapeutic approach without explicit adverse effects. Currently, dietary approaches to managing IBD are limited to the following: (1) exclusion diets-the practice of intentionally eliminating either foods that increase reported symptoms or foods to which the patient develops antibodies-for maintaining remission 10 and (2) enteral/parenteral nutrition for maintaining caloric intake and inducing remission during severe symptomatic periods. The use of enteral nutrition is widely recommended for pediatric Crohn disease, but limited evidence supports the translation of this therapy to adults. 11 Restrictive diets, such as the specific carbohydrate diet, have also demonstrated efficacy in a pediatric population. 12, 13 A growing body of preclinical Figure 1 The inflammatory environment and impaired mucosal barrier in active inflammatory bowel disease (IBD). In the healthy gut, intestinal epithelial cells, macrophages, neutrophils, dendritic cells, and T lymphocytes help maintain intestinal homeostasis. These immune cells, along with the epithelial tight junctions, the secreted mucus, the low pH, the antimicrobial peptides, and the endogenous proteases, constitute a physical, chemical, and immunological barrier to the entry of toxins and pathogens. In IBD, however, an abnormal immune response ensues. Stimulated by local innate immune cells, naive T lymphocytes differentiate into T-helper cells and secrete inflammation-associated cytokines and chemokines. Neutrophils migrate to sites of tissue inflammation and undergo degranulation, releasing enzymes (proteases, myeloperoxidase), cytokines, and reactive oxygen species to kill pathogens and attract additional leukocytes to the region. The pathogenesis of IBD is characterized by a persistent inflammatory state and alterations in intestinal barrier function that lead to increased permeability. Impaired mucosal healing and declining mucus secretion progress into areas of ulceration. As a result, commensal microbes located in the lumen, along with dietary antigens and toxins, translocate across the intestinal barrier to promote further inflammation. Left unabated, ulcerations eventually lead to perforation and bleeding. Abbreviations: IL, interleukin; RNS, reactive nitrogen species; ROS, reactive oxygen species; TNF-a, tumor necrosis factor a.
evidence indicates that several bioactive molecules found or derived from soybean are capable of modulating GI inflammation and may be useful for prevention of IBD as well as for maintenance of IBD remission, suggesting a possible complementary approach to established nutrition interventions. Soybean (Glycine max) is a species of legume native to East Asia, where it is a staple of the regional cuisine. Naturally high in proteins, monounsaturated fatty acids (oleic acid), omega-3 (n-3) polyunsaturated fatty acids (PUFAs) (eg, a-linolenic acid), omega-6 (n-6) PUFAs (eg, linoleic acid), and complex carbohydrates (eg, cellulose, raffinose, and pectins), soybeans are both a traditional and a modern health food. A large body of evidence supports the view that high soy intake correlates with decreased rates of cancer 14 and cardiovascular disease. 15 The beneficial effects of soy are not attributed solely to soybean's macro-and micronutrient content; instead, decades of research reveal soybeans contain unique phytochemicals and bioactive compounds, such as phytosterols, soyasaponins, and phosphatidylcholine, that confer measureable health benefits ( Figure 2 and Table 1) . [16] [17] [18] [19] [20] [21] [22] [23] Given the limited oral bioavailability and rapid metabolism of many diet-derived bioactive compounds, it is expected that their respective concentrations and biological activities will be greatest within the cells of the intestinal epithelium, including local immune cells. As such, a number of soy-derived bioactive compounds have purported effects on the pathogenesis of IBD and the induction of remission in experimental models of colitis. To date, the anticolitic effects of these bioactive compounds have not been reviewed. The present review collates all pertinent studies investigating the effects of soy protein, as well as the effects of novel soy proteinderived peptides and proteases, on intestinal inflammation. Also examined are the effects of phospholipids, soyasaponin, phytosterol, and isoflavone, all of which are isolated from the common soybean. Since fermentation may modulate the bioactive composition of soybeans, the emerging body of evidence on the anticolitic effects of fermented soybean products is also reviewed.
SOYBEAN PROTEIN FRACTION
The role of dietary proteins in IBD is complex, as indicated by some disagreement in the literature. As in most disease states, dietary protein needs are elevated in IBD, especially during symptomatic periods. 11 Indeed, sufficient protein is necessary to promote anabolism and tissue regeneration as well as to maintain muscle mass, the loss of which is indicative of malnutrition and is associated with increased hospitalization rates and advanced disease states. 24 Nevertheless, the source of dietary protein is important. Several population-level studies showed that high intake of animal proteins may promote the onset of IBD later in life. 25, 26 The association between animal proteins and IBD incidence is not clearly defined but may be related to a proinflammatory effect of heme iron 27 or to Western diet-induced dysbiosis. 25 
Soybean protein concentrates
In addition to supporting the maintenance of muscle mass, soy proteins may have anti-inflammatory properties. A soy protein concentrate significantly inhibited the production of free radicals by colon adenocarcinoma Caco-2 cells treated with hydrogen peroxide. 28 Excess free radical production promotes cellular oxidative stress, which plays a role in IBD pathology, as evidenced by the accumulation of oxidation products in the intestinal mucosa 29 and serum. 30 Accumulation of free radicals in enterocytes is believed to disturb the cell membrane, 31 promote DNA damage, disrupt tightjunction barriers, 32, 33 and activate a proinflammatory immune response. 34 Cotreatment of Caco-2 cells with hydrogen peroxide and graded levels of soy protein concentrate dose-dependently increased cell viability, 28 indicating an enhanced defense against hydrogen peroxide. In dextran sulfate sodium (DSS)-induced colitis, an experimental animal model emulating many aspects of human ulcerative colitis, Bitzer et al 28 showed that dietary supplementation of a casein-based diet with a soy protein concentrate at 6% or 12% (wt/wt) prevented body weight loss, attenuated mRNA and protein expression of proinflammatory cytokines and associated transcription factors, and decreased the activity of the NLRP3 inflammasome, specifically caspase-1 activity. 28 Caspase-1 functions in coordination with responses that promote nuclear factor-kappa B (NF-jB) activity by inducing maturation of the NF-jB-regulated proteins pro-interleukin (IL) 1b (IL-1b) and pro-IL-18. Although activation of NLRP3 is associated with colitis in animals, 35 there is conflicting evidence in the literature regarding the contribution of NLRP3 activation to the severity of disease in animal models and in humans . [35] [36] [37] The possible downregulation of caspase-1 activity by soy protein is certainly relevant, as elevated IL-1b expression is observed in IBD patients and is indicative of a dysregulated Th1 response. 38 In mice, a diet in which soy was the only protein source (20%, wt/wt) was also found to attenuate GI histological changes of IBD, prevent colon shortening, and lessen colonic edema associated with DSS-induced colitis when compared with a casein-based or whey-based diet. 39 Comparisons between amino acid composition and the source of protein concentrates are also relevant, as specific dietary amino acids such as glutamine 40, 41 and arginine 40, 42 may influence IBD progression.
Future studies of soy protein concentrates that compare proteins with well-characterized amino acid profiles in models of colitis are warranted.
Soybean proteins as a source of bioactive peptides
The protein fraction of soy consists primarily of 2 proteins: b-conglycinin and conglycinin. Individually, these proteins are frequently purported to be antigens, producing enterocolitis in infants and stimulating immune responses in individuals with soybean allergies.
Though soybean proteins may be allergenic if consumed raw, they are precursors of biologically active secondary peptides, some that are naturally present in the plant and others that may be produced during digestion and fermentation of soybean products. 43 Soybean-derived bioactive peptides have recently gained attention for their potential use as nutraceutical agents. They are abundant in whole foods 44 and are bioavailable when coadministered with natural protease inhibitors, which protect them from enteric peptidases and proteases. 45 Soy peptides have only recently gained recognition for their anticolitic effects. Early studies showed that a crude soybean di-and tripeptide extract lowered the colonic expression of proinflammatory cytokines, including IL-1b, tumor necrosis factor a (TNF-a), and IL-6 in a porcine model of DSS-induced colitis. 46 In addition, histological markers of colitis, intestinal permeability, and oxidative stress were indistinguishable from those seen in control piglets receiving no DSS. On the basis of this finding, investigators used a combination of highperformance liquid chromatography and liquid chromatography-tandem mass spectrometry to isolate valine-proline-tyrosine (Val-Pro-Tyr) as the active soy tripeptide most readily transported across an in vitro intestinal brush border. 47 In cell culture models, Val-Pro-Tyr was found to have antiinflammatory properties. Treatment with Val-ProTyr at a concentration of only 4mM in TNF-a stimulated Caco-2 cells decreased IL-8 secretion by about 40%. 47 Meanwhile, Val-Pro-Tyr also reduced TNF-a secretion in lipopolysaccharide (LPS)-stimulated monocytic leukemia macrophage (THP-1) cells by about 20%. 47 Val-Pro-Tyr also significantly attenuated cytokine gene expression in the colons of DSStreated BALB/c mice. 47 Although these findings were promising, the authors' determination of the most bioactive soy peptide was based solely on the ability of peptides to be transported intact. Moreover, the experiment did not control for the benefit that might have been provided by accompanying amino acids. Though the available data is encouraging, the mechanisms of action of novel soy peptides in IBD, including Val-Pro-Tyr, remain to be elucidated.
Lunasin, a 43-amino acid peptide originally isolated from soybean, has been under intense investigation for its chemopreventative and anti-inflammatory properties for almost 2 decades. 48 Among other chemopreventative properties, lunasin prevents histone methylation and reduces tumor incidence and proliferation in mouse models of epidermal carcinogenesis. [48] [49] [50] In a transcriptomic analysis of RAW264.7 cells treated with LPS þ lunasin or lunasin alone, lunasin was found to upregulate proapoptotic genes in an NF-jB-dependent manner. 51 As a negative modulator of the NF-jB cascade, lunasin had anti-inflammatory effects in LPStreated RAW264.7 macrophages. 52 Lunasin was also shown to be anti-inflammatory in THP-1 cells 49 and have antioxidant effects in Caco-2 cells. 53 Additionally, treatment with lunasin at a concentration as low as 1mM significantly lowered free radical production by Caco-2 cells in response to hydrogen peroxide exposure. 53 Lunasin appears to be readily bioavailable, which favors its potential use as a dietary therapy. In mice, radiolabeled lunasin was detected in plasma and tissues (including the GI tract) 3 hours after gavage. 45 In humans, approximately 4.5% of orally administered lunasin reached the blood circulation. 54 However, it is important to note that only 3% of orally ingested lunasin resists digestion. 54 On the basis that modulation of NF-jB by soy-derived peptides attenuates experimental colitis, lunasin has considerable potential in future therapeutic applications.
Bowman-Birk inhibitors
Bowman-Birk inhibitors are a class of serine protease inhibitors abundant in legumes, particularly soybeans. In healthy mammals, these inhibitors are typically thought of as antinutrients, interrupting the normal digestion of proteins into amino acids. For this reason, they are inactivated during soy concentrate processing (ie, soy milk, and soy-based animal feed). 55 However, they have also demonstrated antiproliferative effects in colon cancer cell lines 56, 57 and in vivo carcinogenesis models 58 through their actions on endogenous proteases and via induction of endoplasmic reticulum stress-mediated apoptosis. 59 Since serine proteases are also implicated in the dysregulated inflammatory response of IBD, 60 Bowman-Birk inhibitors represent a natural alternative to the protease inhibitor class of pharmaceutical agents currently under investigation.
Bowman-Birk inhibitors also exhibit antiinflammatory effects, specifically in the GI tract. Swiss Webster mice with colitis induced by 5% DSS in drinking water were fed a standard laboratory chow diet supplemented with a 0.5% (wt/wt) Bowman-Birk inhibitor concentrate. When this diet was consumed both during DSS administration and in the post-DSS recovery period, mortality was reduced by 15% compared with that in mice fed a control diet. 61 The diet containing the Bowman-Birk inhibitor concentrate also significantly attenuated histological markers of colonic inflammation during the recovery period following DSS injury. 61 In C57BL/6 mice given 3.5% DSS in drinking water and treated subsequently with purified soy Bowman-Birk inhibitors by gavage, expression of proinflammatory cytokines and Toll-like receptors (TLRs, which drive the inflammatory response of innate immunity) was decreased. 62 It noteworthy that effects on TLRs were limited to transcriptional changes. Although TLR expression was lowered, the activation of TLR and downstream signaling consequences were not characterized in that study. Given the success in experimental models, Bowman-Birk inhibitor concentrate has generated interest for the treatment of IBD in humans. In a recent clinical trial, individuals receiving Bowman-Birk inhibitors showed improvement in the disease activity index as well as remission of ulcerative colitis. 63 The 12-week trial found no serious adverse effects associated with consumption of Bowman-Birk inhibitors, 63 thus providing a solid foundation for further clinical trials with Bowman-Birk inhibitor concentrate.
Although there is support for the therapeutic use of Bowman-Birk inhibitors, the anti-inflammatory mechanism(s) of Bowman-Birk inhibitors have yet to be fully explained. Biologically, the anticolitic effects of Bowman-Birk inhibitors may in part stem from the inhibition of secretion of serine proteases (eg, chymase, b-tryptase, elastase, and cathepsin G) by immune cells. 60 Bowman-Birk inhibitors suppress the activity of these endogenous proteases in vitro. [64] [65] [66] During normal inflammatory responses, the secretion of endogenous proteases is in balance with the expression of endogenous protease inhibitors. However, IBD is associated with a dysregulated immune response and excessive colonic infiltration of immune cells. In fact, while neutrophil-associated proteases accumulate in the intestinal tissue of IBD patients, the expression of leukocyteassociated protease inhibitors is repressed. 67 In turn, excessive protease activity in the lamina propria contributes to the chronic immune response, either through tissue proteolysis 68 or activation of proinflammatory protease-activated receptors. Protease-activated receptor 2, in particular, is expressed in intestinal epithelial cells, especially under conditions of ulcerative colitis. 69 Recently, a novel fermented soy germ extract (Primasoy; Genibio) high in both Bowman-Birk inhibitors and isoflavones improved both microscopic and macroscopic inflammatory markers and reduced intestinal permeability in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. 70 A strength of the study was the inclusion of a group of rats treated with fermented soy germ extract plus an estrogen receptor antagonist (ICI182.780). The combination of the estrogen receptor antagonist and fermented soy germ extract prevented the macroscopic and microscopic improvements seen with fermented soy germ extract alone, indicating that isoflavones were responsible for those improvements. However, the abnormally high expression of protease-activated receptor 2 in rat colon mucosa and the increased fecal proteolytic activity induced by TNBS were attenuated by fermented soy germ extract in the presence of the estrogen receptor antagonist, thus indicating a benefit specific to Bowman-Birk inhibitors. 70 It is not yet clear whether the proposed therapeutic effects of Bowman-Birk inhibitors are of local or systemic influence. Since active Bowman-Birk inhibitors resist digestion, 71 they should reach the colon intact and alleviate colitis. In cannulated pigs, it was estimated that approximately 4% to 7% of ingested Bowman-Birk inhibitors reach the distal ileum and retain their trypsin and chymotrypsin inhibitory activity. 72 Meanwhile, metabolic studies in humans indicated Bowman-Birk inhibitors taken orally are absorbed through the GI tract and are rapidly excreted intact in the urine. Taken together, these studies suggest Bowman-Birk inhibitors act locally in the GI tract as well as systemically. 73 Future studies are needed to better understand the tissue accumulation, the serum distribution, and the ensuing tissue antiprotease activity of Bowman-Birk inhibitors.
SOY LIPID FRACTION
Similar to the effect of dietary protein, the effect of dietary fat on IBD risk and recovery varies, depending on the source and composition of the fat. For instance, the Western diet is high in total fat and, more specifically, high in proinflammatory saturated fats and n-6 PUFAs. Feeding a diet high in milk-derived saturated fat promoted earlier onset of colitis in IL-10 knockout mice by expanding the population of Bilophila wadsworthia in the colon. 74 Nonetheless, several epidemiological studies on this topic have not correlated saturated fat with colitis in humans. 75 Like saturated fat, n-6 PUFAs consumed in excess may drive inflammation in ulcerative colitis by serving as a substrate for the production of hormone-like proinflammatory prostaglandins, leukotrienes, and thromboxanes. 76, 77 On the other hand, balancing n-6 PUFAs with n-3 PUFAs-found in high concentrations in flaxseed oil, fish, and algaeantagonizes this response, displacing arachidonic acid in the plasma membrane to decrease the severity of the inflammatory response. 78 For this reason, a 4:1 ratio of n-6 to n-3 PUFAs is recommended to manage inflammation. Raw soybean oil is not in itself considered a therapeutic dietary supplement because it contains 16% saturated fats by weight and is characterized by a 7:1 ratio of n-6 to n-3 PUFAs. 22 However, the lipid fraction of soybeans serves as a concentrated source of bioactive molecules that may influence the prognosis of IBD.
Phospholipids
Dietary phospholipids are ingested in the form of glycerophospholipids. Given their amphiphilic nature, glycerophospholipids are important structural components of cell membranes in living organisms. Soybeans, naturally rich in fatty acids, are considered a valuable source of dietary glycerophospholipids. Found in the yellow-brown fraction of soybeans known as lecithin, glycerophospholipids are present in the following order of decreasing concentration: phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine (in trace amounts). 79 As mentioned in the Introduction, weakening of the intestinal barrier integrity is key in the initiation of IBD and its symptoms (Figure 1 ). Along with protein mucins, phosphatidylcholine is an essential component of mucus, which acts to block the entry of hydrophobic bacteria and hydrophilic antigens. 80 An early study in rats demonstrated that rectal delivery of glycerophospholipids improved histological signs of colitis and lessened the permeability of the colonic mucosa. 81 The therapeutic potential of phosphatidylcholine in IBD is supported by the observation that patients with ulcerative colitis in remission have decreased levels of phosphatidylcholine and lysophosphatidylcholine (a phospholipase A2 intermediate) in rectal mucus samples. [82] [83] [84] This finding led Ehehalt et al 82 to hypothesize that loss of colonic mucus is involved in ulcerative colitis pathology. In the first of a series of randomly controlled trials that lasted 3 months, patients with ulcerative colitis were given delayed-release lecithin capsules designed to deliver phosphatidylcholine to the colon. In the cohort treated with lecithin capsules, 90% of participants experienced a 50% improvement in clinical disease activity index scores, whereas only 10% of placebo-treated patients achieved the same level of improvement. 83 Of the 90% experiencing some improvement, 53% entered remission during follow-up (vs 10% of control individuals), and 63% experienced significant reduction of the inflamed colon area. 83 In a separate study of the same delayed-release lecithin, 30 participants received steroid drugs plus lecithin capsules. Of these, 14 entered clinical remission and 15 were able to discontinue steroid therapy (control group: 3 of 30 entered remission, and 3 of 30 could discontinue steroids). 84 The mucus-regenerating properties of phosphatidylcholine extend even to patients who are resistant to conventional ulcerative colitis therapies. 5-Aminosalicylic acid (a pharmaceutical agent most commonly prescribed as mesalazine) is often prescribed to patients as a first step in the treatment of IBD and has demonstrated efficacy in inducing and maintaining remission in mild to moderate colitis. 85 However, many patients have refractory ulcerative colitis. Such patients present with active colitis despite receiving the most appropriate treatment available. In a multicenter placebocontrolled study, a novel delayed-release phosphatidylcholine formula improved clinical response in mesalazine-refractory patients; 77% of treated individuals improved vs 60% in the placebo group. 86 The delayed-release phosphatidylcholine also led to histological remission and some improvement in the remission rate (P ¼ 0.12). 86 In addition, the study expanded upon previous results by demonstrating a longitudinal benefit of phosphatidylcholine supplementation, as treated individuals were significantly less likely to relapse during follow-up. 86 A clinical trial is currently recruiting study participants to expand upon the longitudinal effects of phosphatidylcholine supplementation reported by Karner et al. 86 Overall, a growing body of evidence supports the therapeutic benefit of phosphatidylcholine in ulcerative colitis. The success reported in human studies is expected to raise interest in soybean phosphatidylcholine supplementation to promote secretion of mucus in the colon and to improve outcomes in patients with UC. However, the mechanisms by which phosphatidylcholine stimulates mucus secretion or improves mucus layer integrity have not been described in detail, which has hindered progress in the field. Investigations of mucus loss and replenishment in the inflamed colon would prove valuable to the understanding of ulcerative colitis pathophysiology.
Soyasaponins
Saponins are naturally occurring, amphipathic, glycoside conjugates named for their soap-like foaming properties. Soybeans contain various triterpenoid saponins, termed soyasaponins. 87 Currently, 36 soyasaponins have been identified and grouped on the basis of their functional groups, generally referred to as group A, B, E, and DDMP (2,3-dihydro-2,5-dihydroxy-6-methyl-4H-pyran-4-one) soyasaponins. 88 Aglycone soyasaponins-termed soyasapogenols-are produced either through the processing of soyasaponins or during their endogenous digestion and, importantly, retain biological activity. 87 In their natural form, soyasaponins are poorly absorbed by the GI tract, owing to extensive first-pass metabolism. When administered to humans, soyasapogenols, but not soyasaponins, are detected in the feces 89 and in colon homogenates, but not in plasma or urine. 90 This suggests soyasaponins undergo deglucosidation in the GI tract to the corresponding aglycone, which is taken up locally in the intestine but does not reach the blood circulation. Nonetheless, soyasaponins and soyasapogenols affect gut health.
Early evidence of the potential benefit of soyasaponin supplementation in colitis was promising. Despite limited oral bioavailability, soyasaponins exerted beneficial effects in the colon. Crude soyasaponin extracts demonstrated anticancer potential as well as antioxidant properties in a mouse model of colon tumorigenesis. 91, 92 Furthermore, the anti-inflammatory effects of soyasaponins were observed in vitro and in mouse models of intestinal inflammation. Treatment of LPSstimulated mouse peritoneal macrophages with soyasaponins lessened the secretion of proinflammatory mediators regulated by NF-jB. Specifically, soyasaponins decreased the secretion of prostaglandin E 2 , [93] [94] [95] TNF-a, [93] [94] [95] monocyte chemoattractant protein 1, 93 IL1b, 94, 95 and nitrite [93] [94] [95] by peritoneal macrophages. In similar fashion, soyasaponins administered by gavage at 10 or 20 mg/kg of body weight decreased the expression of IL-1b, IL-6, IL-10, and TNF-a in the colon of TNBStreated ICR mice. [94] [95] [96] Colonic activity of the antioxidant enzymes superoxide dismutase and catalase was also significantly increased. 94 On the basis of changes observed in the aforementioned studies, 53, [93] [94] [95] it was predicted that soyasaponins would prevent NF-jB activation by precluding IjBa degradation 93 in mouse peritoneal macrophages. Indeed, soyasaponins decreased luciferase activity of an NF-jB reporter plasmid transfected to RAW264.7 macrophages. 97 Further examination revealed that soyasaponins A and B upregulated superoxide dismutase, thereby abating free radical accumulation and repressing NF-jB upstream of the PI3K/ Akt/NF-jB signaling pathway. 98 In macrophages, TLR4 activation results in the production of intracellular reactive oxygen species, which in turn activate PI3K/Akt signaling. By inhibiting the binding of LPS to TLR4 in peritoneal macrophages, soyasaponin A regulated the canonical branch of TLR4-mediated NF-jB activation (Figure 3) . 95 In sum, soyasaponins prevent excessive activation of the innate immune response in a TLR4-dependent manner and through inhibition of PI3K/ Akt/NF-jB signaling.
To date, the mechanistic studies of the antiinflammatory effects of soyasaponins have drawn some criticism. First, soyasaponins have poor bioavailability, and there is no evidence that intact soyasaponins would reach peritoneal macrophages in vivo. Second, the bioactivity of soysapogenols in enterocytes has not been reported. Third, although the cytotoxicity of soyasaponins has been assessed in carcinoma and primary cell lines, 99 ,100 the safety of orally administered soyasaponins or sapagenols has not been ascertained in vivo. Finally, there has only been a single in vivo investigation of the anticolitic effects of soyasaponins. Therefore, it is too early to draw conclusions about the potential of soyasaponins as therapy for IBD.
Soy phytosterols
Though structurally similar to cholesterol (Figure 2 ), phytosterols and phytostanols are plant-derived, cholesterollowering compounds with documented effects on the risk of cardiovascular disease. The US Food and Drug Administration (FDA) acknowledges that "Foods containing at least 0.65 grams of vegetable oil sterol esters, eaten twice a day with meals for a daily total intake of at least 1.3 grams, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease." 101 Although more than 200 structurally unique phytosterols have been identified, 102 the primary phytosterols in soybeans include, in order of increasing concentration, stigmasterol, campesterol, and b-sitosterol. 103 In a Finnish population consuming a representative Western diet, the intake of dietary phytosterols ranged from 150 to 450 mg/d, 104 markedly lower than the intake levels recognized by the FDA to provide a health benefit. Furthermore, phytosterols are generally considered to have low bioavailability, ie, about 4% to 5% for b-sitosterol and stigmasterol and 10% for campesterol. 105 Although the cholesterol-lowering effects of phytosterols are widely recognized, phytosterols are also recognized for their antiinflammatory effects 106 and regulation of gene expression through interactions with nuclear receptors. 107, 108 The bioactivity of soy phytosterols has translated positively to experimental models of colitis. The benefits of phytosterols in experimental colitis were first reported with guggulsterone, a phytosterol derived from the resin of Commiphora trees. When guggulsterone was administered by gavage to mice at 100 mg/kg of body weight, it was found to reduce the symptoms of colitis. 109 In intestinal epithelial cell lines Caco-2 and IEC-18, a solution of 50mM guggulsterone inhibited the NF-jB pathway to reduce inflammation.
109 b-Sitosterol, the prevalent phytosterol in soybeans, exhibited immunomodulatory properties similar to those of guggulsterone. b-Sitosterol (10 and 20mM) decreased the phosphorylation of 2 NF-jB intermediary proteins, IKKb and IjBa, by directly inhibiting the binding of LPS to TLR4 in peritoneal macrophages (Figure 3) . 110 Favorable effects of b-sitosterol on experimental colitis have been reported in several in vivo models of colitis, including TNBS-, 96 acetic acid-, 111 and DSSinduced colitis 112 as well as adoptive T-cell transfer into immunodeficient Rag1 knockout mice. 113 Phytosterols have the ability to regulate innate immunity, which may explain, in part, their therapeutic effects on colitis. The first suggestion of this came when investigators observed an increase in regulatory T cells among peripheral monocytes isolated from asthma patients treated with phytosterols. 114 Subsequently, the same group performed transcriptomic analysis on jejunal biopsies from healthy individuals fed a phytosterol-rich shake. They reported a shift in gene expression toward anti-inflammatory pathways associated with T-cell activation and proliferation 5 hours after consumption of phytosterols. 115 Moreover, there is evidence to suggest that phytosterol-induced changes in T cells can influence colitis pathology. One study in Rag1 knockout mice-a model that develops colitis when injected with exogenous CD4 þ CD45RB hi T cells-found that feeding phytosterols at 2% of the diet increased the number of regulatory T cells in colon tissue and reduced CD3 þ T-cell positive staining in mice, a marker of colitis severity. 113 The anticolitic effects of phytosterols may, however, be dependent on their cholesterol-lowering properties. In T cells, cholesterol metabolism plays an important role in Figure 3 Soybean bioactive compounds block key proinflammatory and antiapoptotic pathways that are upregulated in inflammatory bowel disease (IBD). Signaling via the JAK/STAT and TLR4/NF-jB pathways is frequently upregulated in immune cells and enterocytes in the chronic inflammatory environment of IBD. The JAK/STAT pathway is activated by proinflammatory cytokines such as interleukin 6 (IL-6), tumor necrosis factor a (TNF-a), and interferon c (IFN-c) . This activation promotes differentiation of immune cells, thereby propagating the inflammatory response. Meanwhile, activation of the TLR4/NF-jB pathway leads to upregulation of proinflammatory cytokine secretion and chemokine secretion as well as transcription of proinflammatory enzymes cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS). Soybean-derived bioactive compounds such as isoflavones, phytosterols, soyasaponins, Bowman-Birk protease inhibitors, and dietary peptides inhibit specific steps of the JAK/STAT and TLR4/NF-jB signaling pathways to mitigate IBD. Abbreviation: IFN, interferon.
the activation of the adaptive immune response. 116 Specifically, oxysterols, the products of cholesterol metabolism, inhibit cholesterol synthesis in T cells by acting as ligands of liver X receptor b (LXRb). 117 Upon T-cell activation, oxysterols are sulfated and in turn no longer bind LXRb. As a result, T-cell cholesterol metabolism shifts to favor cholesterol synthesis in order to support proliferation. 117 In genetic mouse models, knocking out LXRb but not LXRa heightened the severity of both DSS-and TNBS-induced colitis, with a significant shift in CD3 þ and CD4 þ (activated) T cells in the lamina propria of the colon. 118 4-Desmethyl phytosterols, which include b-sitosterol and campesterol, act as ligands for LXRa and LXRb in vitro, 119 possibly explaining the observed anti-inflammatory benefits of phytosterol. Additionally, cholesterol is believed to act as a damageassociated molecular pattern when it stimulates the NLRP3 inflammasome, 120 thereby promoting colitis 121 and colorectal cancer. 122 Finally, the role of dietary cholesterol in inflammation was established when ezetimibe, a cholesterol-lowering drug, decreased dietary cholesterol-induced immune cell recruitment in the intestine of zebrafish. 121 It is argued that the observed in vivo effects of phytosterols on colitis are highly model dependent. Illustrating this are the results of 2 experiments utilizing the DSS-induced colitis model. Dietary supplementation with phytosterols and phytostanols conferred no significant benefits in a C57BL/6 mouse model of 1.5% DSS-induced colitis. 113 However, in BALB/c mice given 5% DSS, clear benefits to clinical signs of colitis progression, oxidative stress, and histological markers were observed. 112 Further complicating the comparison of these 2 studies is the markedly different dose of phytosterols used, 2% vs 0.2% of the diet. In addition, the severity of DSS-induced colitis is affected by the gender, gut microbiome, and age of the model. 123 Therefore, this field of research would benefit from the standardization of experimental protocols. Furthermore, long-term application of phytosterols to humans with IBD should be considered carefully. The chronic systemic inflammation that accompanies IBD may increase the risk of dyslipidemia and cardiovascular disease. 124 Though disputed, a body of research indicates an increase in circulating phytosterols is correlated with increased risk of cardiovascular disease mortality, 125, 126 potentially contraindicating phytosterol therapy in this population. Despite the promise shown by phytosterols in experimental studies, there is still much more research needed before these findings can be translated to a human population.
Isoflavones
Isoflavones are the most recognized class of soybeanbioactive compounds. Isoflavones are flavonoid polyphenols noted for their structural similarity to estradiol, and as such act as ligands of the estrogen receptors. In soybeans, genistein and daidzein are the predominant isoflavones, with glycitein present in low levels. Isoflavone concentration and structure (glycone conjugation) vary widely between soybean products ( Figure  4 ). Isoflavones are further modified or degraded by processing, manufacturing, and storage conditions, 127 ,128 all of which can potentially alter their bioavailability and bioactivity. 129 The isoflavones in soy are recognized for their anticarcinogenic, antiinflammatory, and antioxidant properties, among other attributes.
Extensive preclinical evidence regarding the role of isoflavones in IBD is available (Table 2; 33,130-137,138 Table 3) . 134, [139] [140] [141] [142] [143] [144] [145] Isoflavones are thought to act as antioxidants in patients with colitis. Isoflavonic compounds 25-50mM) decreased baseline SOD activity Genistein (at 25-100mM) and daidzein (at 25-50mM) protected against oxidized oleic acid-induced cell membrane damage and DNA damage Genistein (at 25-100mM) and daidzein (at 50mM) protected against oxidized oleic acid-induced conjugated diene production Kameoka et al (1999) 137 Caco-2 cells Genistein (100 mM)
Activity of antioxidant enzymes
Increase in metallothionein; no change in SOD or catalase Abbreviations: COX-2, cyclooxygenase 2; IFN-c, interferon c; IL, interleukin; iNOS, inducible nitric oxide synthase; IjB, inhibitor of nuclear factor kappa B; IjBa, inhibitor of nuclear factor kappa B, alpha; IP-10, interferon-c-induced protein 10; LPS, lipopolysaccharide; NF-jB, nuclear factor-jB; NO, nitric oxide; RNS, reactive nitrogen species; SOD, superoxide dismutase; TEER, trans-epithelial electrical resistance; TNF-a, tumor necrosis factor a; ZO-1, zonula occludens 1. 137 Daidzein also induced catalase activity while decreasing superoxide dismutase activity in unstimulated Caco-2 cells, but not when the cells were challenged with lipid hydroperoxides. 136 Possibly owing to their antioxidant activities, genistein and daidzein improved tight-junction permeability (measured by lactate dehydrogenase leakage) and prevented DNA oxidative damage in lipid hydroperoxide-stimulated Caco-2 cells. 136 As an inhibitor of tyrosine kinase, genistein may also play an alternative role in protecting intestinal barrier function from free radical damage. Indeed, at high concentrations (300mM), genistein prevented oxidative stress-induced tyrosine kinase-mediated phosphorylation of the tight-junction proteins occludin and zonula occludens 1, thereby averting breakdown of the intestinal epithelial barrier. 33 The function of isoflavones in regulating antioxidant enzymes has been demonstrated in in vivo studies. SENCAR mice fed a diet containing purified genistein at 50 ppm or 250 ppm for 30 days had significantly higher activity of catalase, glutathione reductase, and glutathione S-transferase in the small intestine. 139 Feeding tofu to rats increased the activity of superoxide dismutase and catalase in the small intestine above that seen with an equivalent amount of crude isoflavone extract. 140 BALB/c mice fed a 0.5% soy isoflavone diet (wt/wt) also presented significant increases in mRNA levels of superoxide dismutase and glutathione peroxidases 1 and 4.
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In addition to preventing colitis through antioxidant mechanisms, soy isoflavonic compounds show notable anti-inflammatory effects in vitro and in vivo. Treatment with genistein inhibited the secretion of proinflammatory cytokines in Caco-2 cells (IL-6, IL-8) 130, 138 and MODE-K primary murine intestinal epithelial cells (IL-6, IL-8) 133 as well as in the colons of BALB/c mice treated with 0.6% genistein (wt/wt) in the diet (IL-1b, IFN-c, IL-17). 145 Likewise a novel daidzeinrich isoflavone supplement significantly decreased secretion of proinflammatory cytokines from Mono Mac 6 human macrophages and colitic mousederived mesenteric lymph node cells. 134 Multiple other cell models of breast cancer, 148 Parkinson disease, 149 and liver carcinoma 150 exhibited an interruption of the NF-jB signaling cascade after treatment with isoflavones. 151 However, in intestinal epithelial cell models of inflammation, this mechanism appeared to be less predominant. For instance, isoflavones prevented IjBa phosphorylation in LPS-stimulated IEC-18 cells 131 -thereby blocking NF-jB activity-but not in Caco-2 Colonic inflammation due to DSSinduced colitis; tight-junction protein expression
Genistein attenuated DSS-induced changes in colon length and body weight Genistein decreased colonic cytokine gene expression of IL-1b and IFN-c DSS-induced changes in expression of tight-junction proteins ZO-1 and occludin were attenuated by genistein supplementation Abbreviations: COX-2, cyclooxygenase 2; DAI, disease activity index; DRIA, daidzein-rich isoflavone aglycone; DSS, dextran sulfate sodium; GPX, glutathione peroxidase; GST: glutathione S-transferase; IFN-c, interferon c; IL, interleukin; LPS, lipopolysaccharide; MLN, mesenteric lymph node; MPO, myeloperoxidase; PAM, palmitoyl 3 -cysteine-serine-lysine 4 ; SOD, superoxide dismutase; TLR4, Toll-like receptor-4; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TNF-a, tumor necrosis factor a; ZO-1, zonula occludens 1; Zn/Cu, zinc/copper. cells stimulated with TNF-a 133 or IL-1b. 130 In fact, genistein is sometimes observed to activate the NF-jB signaling pathway in intestinal epithelial cells, 130, 131 indicating genistein exerts its anti-inflammatory effects in a manner independent of NF-jB.
Activation of the Janus kinase (JAK) signal transduction and activator of transcription (STAT) pathway via cytokine signaling represents another possible route by which isoflavones modulate inflammation in intestinal epithelial cells. The STAT family of proteins consists of transcription factors capable of interacting with JAK proteins. JAK proteins are tyrosine kinases associated with membrane-bound receptors to which proinflammatory cytokines act as ligands. Once activated, JAK phosphorylates STAT, and then STAT dimerizes and translocates to the nucleus to act as transcription factor (Figure 3) . The interplay between STAT, in particular STAT3, and colitis is complex and has been the subject of several reviews. [152] [153] [154] [155] Studies have shown that phosphorylation of STAT1 or STAT3 in intestinal epithelial cells promotes proliferation and is necessary for mucosal healing. 156, 157 Meanwhile, activation of STAT in CD4 þ T cells is required for differentiation into 1 of the T-helper phenotypes (ie, Th1, Th2, and Th17) during inflammation. Aberrant STAT phosphorylation is implicated in the development of chronic inflammation, as activation of STAT will produce an exacerbated response of T-helper cells by inhibiting apoptosis of immune cells. 158 In humans, it is observed that expression of STAT is upregulated in the intestinal mucosa 156 and contributes to inflammation 153, 158 and IBD pathogenesis. 153 Isoflavones have been observed to modulate JAK-STAT activity in vivo in intestinal epithelial cells (Figure 3) . In Caco-2 cells, treatment with genistein at a concentration as low as 3mM decreased STAT3 translocation by 56%, whereas treatment with a concentration of 30mM decreased STAT1 nuclear translocation by 23%. 138 Similarly, genistein inhibited LPS-induced STAT1 translocation in murine macrophages. 159 Since JAKs are tyrosine kinases, it is possible that the inhibition of STAT translocation stems from genistein's role as a tyrosine kinase inhibitor. 138, 160 The inhibition of STAT by genistein and perhaps other soy isoflavones is viewed as the main mechanism of action of genistein in inflammatory disease. It has been observed in the pancreas, 161 lungs, 162 liver, and intestine. 138 The estrogen receptors a and b are considered the canonical target of isoflavones. The affinity of isoflavones for binding these essential receptors has resulted in some negative perceptions about soy products among lay public. Some of these fears are well founded, as the potential negative effects of soy exposure on breast cancer remains incompletely understood. 163 Other concerns, such as proposed effects on male fertility 164 and on menstruation in premenopausal women 165 appear to be minimal at the levels isoflavones are consumed in the Western world. Presently, the role of isoflavone-induced estrogenic activity has not been explicitly examined in experimental models of IBD. The activation of estrogen receptor b, however, may be important to control aberrant inflammation in IBD pathology. Experimental studies have demonstrated that estrogen receptor b activation is associated with decreased acute inflammation in vivo 166 and decreased epithelial permeability of ex vivo human colon explants. 167 Contrary to the promising results observed thus far, several reports indicate that isoflavones exacerbate experimental colitis. For instance, the administration of an isoflavone-enriched diet to Wistar rats throughout pregnancy and lactation increased the susceptibility of the offspring to TNBS-induced colitis, 141 a model of acute, localized inflammation of the colon. In this study, the major indications of increased inflammation were elevated colonic myeloperoxidase and increased colon weight. Taken together these changes suggested edema and leukocyte infiltration. 141 Despite this evidence of an immune response, there were no differences in colon histology, immune cell populations, or animal condition between the groups. Equol is a metabolite of daidzein produced by gut bacteria 168 or through fermentation with a variety of starter cultures. 169 Yet in a recent study of acute colitis, Sakai et al 143 found isoflavones either produce no benefit or negatively impact colitis. In particular, equol exacerbated weight loss in mice, resulting in survival of only 14% of equol-treated mice. 143 Thirty percent to 50% of humans are defined as equol producers, 170 with individual variations depending on genetics, demographics, lifestyle, and dietary factors. 170, 171 Equol producers have significantly higher levels of equol in the urine and blood plasma following consumption of purified isoflavones or equoldepleted soy supplement. Urinary equol concentrations found in equol producers amount to 10 to 1000 times that of nonproducers fed a soy protein supplement. 172 The exacerbated manifestations of colitis attributed to isoflavone administration included changes in colon weight and length, accelerated weight loss, and decreased survival. 143 To date, isoflavones have produced negative effects in 2 studies of chemically induced experimental colitis. 141, 143 Although these animal models are adequate for studying intestinal inflammation, variations in the gut microbiota have been observed and linked to diet and husbandry. In contrast, 2 recent studies utilizing a model of DSS-induced colitis found isoflavones to confer a benefit. 144, 145 These 2 studies administered 30-fold 145 and 50-fold 144 higher doses of isoflavones than the dose used by Sakai et al. 143 Contrasting evidence concerning isoflavone supplementation for colitis has also been found in a model of TNBS colitis. Seibel et al 141 reported an increased susceptibility to inflammation in rats exposed to isoflavones throughout their lives. 141 Yet if the dams were not exposed to isoflavones, isoflavone supplementation reduced myeloperoxidase activity and cyclooxygenase 2 (COX-2) mRNA expression in rats. 142 Thus, it may be inferred that populations of IBD patients (ie, equol-producing) may not benefit from soy isoflavone supplementation. Overall, the current preclinical evidence supports the translation of isoflavone supplementation to clinical IBD trials.
FERMENTED SOY PRODUCTS
Scientific advances in microbiology and bioinformatics have led to a greater appreciation of the relationships between microbes and human health. Fermented preparations of soy are popular in Asian countries for their palatability and perceived health properties and have recently gained worldwide popularity for their potential health-promoting and probiotic activities. Biochemically, fermentation alters the bioactivity of soy foods by (1) increasing the levels of bioactive peptides and their metabolites, 169, [173] [174] [175] (2) releasing aglycones from isoflavone glycosides, 127 and (3) lessening the allergenicity of soy proteins. 176 In addition, bacteria starter cultures may themselves be prebiotic, thereby altering the host's gut microbiome. Collectively, these effects position fermented foods a priori favorably as functional foods for ameliorating chronic inflammatory illnesses.
Soy sauce, a popular fermented condiment, has potential for modulating experimental colitis in mice. C57BL/6 mice treated with 2% DSS and fed a diet supplemented with traditionally fermented soy sauce showed significantly lowered colitis-associated production of the cytokines TNF-a (48%), IL-6 (18%), and IFN-c (35%) in their colons compared with mice fed no soy sauce. 177 Soy sauce also inhibited the transcription of inducible nitric oxide synthase and COX-2 in the colon of these mice. It is worth noting that commercial soy sauce is produced through acid hydrolysis and uses defatted soybean. The resulting product contains less total phenol and has lower anti-inflammatory potency than traditionally fermented soy sauce. 177 Though high in salt, soy sauce prevented macroscopic and histological changes associated with DSSinduced colitis. This is in stark contrast to the notion that a diet high in salt promotes GI cancers 178 and exacerbates experimental colitis. [179] [180] [181] Increasing the dosage of soy sauce from 4 to 8 mL/kg of body weight nullified the benefits of soy sauce supplementation, suggesting negative effects of excessive dietary sodium. 177 Feeding miso, a fermented paste produced from soybeans, to F344/DuCrj rats decreased the number of precancerous colonic crypts despite miso containing about 2.2% sodium chloride by weight. 182 When rats were fed the base diet devoid of miso but containing sodium chloride (2.2% or 4.4% wt/wt), counts of aberrant crypt foci were unchanged from those in untreated controls receiving no miso and no added sodium. 182, 183 Therefore, sodium chloride may not promote colonic tumorigenesis and other GI cancers as the authors predicted. Though not as high in sodium, Korean doenjang has also demonstrated anticolitic and antitumorigenic properties in rats. 184 Fermented condiments may represent a healthier alternative to salt, which is consumed excessively in the Western diet. 185, 186 There is growing interest in the therapeutic application of fermented foods in preclinical models (Table  4) . 175, 177, 184, 187, 188 Similar to the other bioactive foods outlined in this review, fermented soy products emerged favorably in initial studies, but it is still unclear how they might withstand further scrutiny. The available evidence does not indicate how fermented foods modulate inflammation. To date, no study has attempted to compare a fermented product against the sum of its bioactive components. Instead, test compounds are typically administered as whole food compounds or crude extracts, which may be made soluble and delivered intragastrically to mice or, alternatively, offered to test animals in a purified diet. These foods contain bioactive compounds, probiotics, and metabolic byproducts of microbes, many of which are not yet characterized even though they may ameliorate colitis. This raises the question whether these compounds have additive or synergistic effects or are active components in fermented foods that serve merely as vehicles. Other challenges for investigators include determining the composition of the test compound, sourcing the test product, and choosing a starter culture.
SOYBEAN BIOACTIVE COMPOUNDS IN CLINICAL AND EPIDEMIOLOGICAL STUDIES
The effects of soybean products and soybean-derived bioactive compounds in human IBD are still unclear.
Yet with the exception of soy lecithin, neither soybeans nor soybean-derived bioactive compounds have been examined in clinical studies as therapies for IBD. Since postmenopausal women receiving hormone replacement therapy have an increased risk of ulcerative colitis, clinical investigations have focused on the role of isoflavones as estrogen receptor agonists. Related studies investigating the effects of soy supplementation on Bax and decreased antiapoptotic protein Bcl-2. Tumor suppressor p53 expression increased and cell cycle inhibitor p21 increased Abbreviations: AOM, azoxymethane; COX-1, cyclooxygenase 1; DSS, dextran sulfate sodium; Exp, experiment; FSS, fermented soy sauce; HF, high fat; HFD, high-fat diet; IFN-c, interferon c; IgA, immunoglobulin A; IL, interleukin; iNOS, inducible nitric oxide synthase; LF, low fat; LFD, low-fat diet; MLN, mesenteric lymph node; MPO, myeloperoxidase; SOD, superoxide dismutase; TNF-a, tumor necrosis factor a. inflammation in postmenopausal women have provided additional insight into the use of soy-derived bioactive compounds in IBD. In a review of clinical trials, Beavers et al 189 reported no consistent effect, either positive or negative, of isoflavone supplementation on circulating cytokines (TNF-a and IL-6). However, the interpretation of results was limited by notable differences in the exclusion criteria of the reviewed trials (in particular, the presence or absence of metabolic syndrome) as well as common biases associated with participant compliance and diet recording.
Presently, the only population-level study on soy food intake and IBD incidence is a single case-control study based on self-reporting of diet in a Japanese population. In this report, Ohfuji et al 190 concluded that females with the greatest consumption of soy isoflavones presented with a significantly increased risk of ulcerative colitis (odds ratio ¼ 4.76; P ¼ 0.02). However, extrapolation of their findings to Western populations is hindered by marked differences in soy and isoflavone consumption patterns. In direct contrast to the conclusions of Ohfuji et al, 190 1 study in Chinese women reported an anti-inflammatory effect of soy consumption, 191 while another meta-analysis reported decreased rates of colon cancer, 192 for which IBD is a risk factor. Given the extensive body of preclinical evidence on soy-derived bioactive compounds and inflammation but the limited epidemiological evidence supporting the consumption of soy products, there is an urgent need for epidemiological investigations of soy product consumption and IBD incidence.
Population-level intake studies may offer only a simplistic perspective of how soy products may affect health. As when evaluating other factors that often confound nutritional epidemiology, such as known associations between exercise, income status, and nutritional quality of diet, measuring individual consumption of whole soy products may not be adequate to correlate the bioactive components of soy with disease risk. Some components of soy foods, though beneficial in a healthy intestine, may induce symptoms in IBD patients. For example, whole soybean preparations such as edamame and soy nuts are high in dietary fiber and thus are associated with lower rates of IBD in epidemiological studies. 193 In contrast, clinical trials have found that specific carbohydrate diets, which restrict most complex carbohydrates, induce remission in pediatric Crohn disease. 12, 13 Food intolerances commonly observed in IBD patients may be related to immune-mediated reactions to dietary allergens. As mentioned in the section Soybean proteins as a source of bioactive peptides, soybean proteins are among the most common food allergens. Though epidemiological studies suggest plant protein consumption can prevent IBD, a cohort of Chinese IBD patients presented with food allergenspecific immunoglobulin G more frequently (72.3%) than did healthy control participants (33.1%). 194 Moreover, 43% of patients diagnosed with Crohn disease presented with immunoglobulin G specific to soybean allergens. 194 Fermentation of soybean may represent a strategy to mitigate the proposed immunoreactivity to soybean proteins in IBD patients. 176, 195 CONCLUSION Soybeans have been a source of nutrition to humans for thousands of years. Only recently has research revealed the potential broad benefits of consuming soybean products. In addition to being rich in essential microand macronutrients, soybeans contain a plethora of antioxidants and immunomodulatory molecules, many of which are unique to soy. The notion that IBD, a debilitating chronic inflammatory disease, could be modulated by diet has generated enthusiasm among nutrition scientists. Over the years, substantial advances have been made in understanding the effects of soybean-derived bioactive compounds on IBD. Soybean bioactive compounds have been shown to lessen oxidative damage, attenuate the immune response, and bolster the intestinal barrier to block entry to pathogens. Furthermore, these compounds are generally considered to be safe. Soybean lecithin, soy protein isolates, and soy phytosterols have been used extensively in humans and, in the case of phytosterols, have recognized health benefits.
The current state of knowledge is far from complete. Dietary bioactive compounds work through many regulatory targets to produce their desired effects, and a complete characterization of each product's biochemical mechanisms is complex. Given the variable etiology of IBD, it would be valuable to understand the potential negative interactions between soybean bioactive compounds and IBD pharmaceuticals. Products such as soy protein isolate and bioactive peptides have received limited attention. The evidence obtained to date justifies further investigation of the properties and mechanisms of action of Bowman-Birk inhibitors, soyasaponins, and even phytosterols. Overall, preclinical studies of the aforementioned bioactive compounds are promising, but these early efforts need to be broadened to models of chronic IBD and to humans with and without IBD. Finally, the evidence presented here suggests that many soybean-derived bioactive compounds have overlapping anti-inflammatory mechanisms. Thus far, however, exploration of additive or synergistic effects of these compounds, including within the context of IBD, is lacking in the literature. This should provide impetus for future studies.
